Pacer Advisors’s Novavax NVAX Stock Holding History

Pacer Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,489	Closed	-$18.9K	–	2648
2024 Q2	$18.9K	Sell	1,489 -6,339	-81%	-$63.8K	﹤0.01%	3439
2024 Q1	$37.4K	Buy	+7,828	New	+$36.3K	﹤0.01%	3288
2021 Q2	–	Sell	-380	Closed	-$69K	–	1503
2021 Q1	$69K	Sell	380 -666	-64%	-$133K	﹤0.01%	1383
2020 Q4	$117K	Sell	1,046 -1,260	-55%	-$134K	﹤0.01%	1340
2020 Q3	$250K	Buy	+2,306	New	+$281K	0.01%	1153
2018 Q4	–	Sell	-3,012	Closed	-$113K	–	886
2018 Q3	$113K	Buy	+3,012	New	+$84.8K	﹤0.01%	1078

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Pacer Advisors's NVAX Position: Q3 2024 in Review

Pacer Advisors sold out of Novavax (NVAX) in Q3 2024, closing a stake of 1,489 shares — an estimated $18.9K sold.

Pacer Advisors first reported a position in NVAX in Q3 2018 and held it in 6 quarters. The position peaked at $250K in Q3 2020. 237 funds tracked by Wall St. Rank hold NVAX as of Q3 2024.

Pacer Advisors reported no remaining Novavax position as of Q3 2024 after selling out during the quarter.
Pacer Advisors sold 1,489 Novavax shares in Q3 2024, an estimated $18.9K.
Pacer Advisors first reported a position in Novavax in Q3 2018 and held it in 6 quarters.
Pacer Advisors's Novavax position peaked at $250K in Q3 2020.
237 funds tracked by Wall St. Rank held Novavax as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.